HC Wainwright Has Bearish Estimate for Cybin Q3 Earnings

Cybin Inc. (NYSE:CYBN - Free Report) - Investment analysts at HC Wainwright lowered their Q3 2025 earnings estimates for Cybin in a research note issued on Tuesday, November 19th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.53) for the quarter, down from their prior estimate of ($0.38). HC Wainwright has a "Buy" rating and a $190.00 price objective on the stock. The consensus estimate for Cybin's current full-year earnings is ($3.37) per share. HC Wainwright also issued estimates for Cybin's Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($3.63) EPS, Q1 2026 earnings at ($0.57) EPS, Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.79) EPS, FY2026 earnings at ($2.69) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at $4.22 EPS and FY2029 earnings at $9.57 EPS.

A number of other brokerages have also recently commented on CYBN. Canaccord Genuity Group lowered their target price on Cybin from $96.00 to $86.00 and set a "buy" rating on the stock in a report on Thursday, November 14th. Cantor Fitzgerald restated an "overweight" rating on shares of Cybin in a report on Wednesday, July 31st.

Cybin Stock Performance

Cybin stock opened at $11.14 on Thursday. The stock has a 50-day simple moving average of $9.52. Cybin has a 52 week low of $6.50 and a 52 week high of $21.66.

Institutional Trading of Cybin

A number of institutional investors and hedge funds have recently bought and sold shares of CYBN. RA Capital Management L.P. purchased a new position in shares of Cybin in the 1st quarter valued at $24,041,000. Rosalind Advisors Inc. lifted its stake in shares of Cybin by 38.3% during the second quarter. Rosalind Advisors Inc. now owns 19,300,000 shares of the company's stock worth $5,230,000 after purchasing an additional 5,340,000 shares in the last quarter. Ikarian Capital LLC purchased a new stake in shares of Cybin in the first quarter worth about $5,770,000. AWM Investment Company Inc. acquired a new stake in shares of Cybin in the first quarter valued at about $930,000. Finally, AdvisorShares Investments LLC lifted its position in Cybin by 13.4% during the 2nd quarter. AdvisorShares Investments LLC now owns 1,865,217 shares of the company's stock worth $494,000 after acquiring an additional 220,403 shares in the last quarter. Institutional investors and hedge funds own 17.94% of the company's stock.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.